| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | [hPG80 and cancer: A new blood biomarker in development for patient monitoring] |
| Creator | You et al. |
| Author | Eric Assenat |
| Author | Léa Payen |
| Author | Thibault Mazard |
| Author | Olivier Glehen |
| Author | Sara Calattini |
| Author | Laurent Villeneuve |
| Author | Gaëlle Lescuyer |
| Author | Bérengère Vire |
| Author | Marc Ychou |
| Abstract | Recent technological advances coupled with our improved understanding of the molecular and cellular mechanisms associated with cancer development have enabled better overall patient care. Among the newly identified biomarkers such as circulating tumor DNA or circulating tumor cells, hPG80 (circulating progastrin) that is easy to detect and quantify by a simple ELISA assay has the potential to become a new routine clinical tool in oncology if on-going studies validated its utility. Indeed, on the one hand, hPG80 was found in the blood of patients with different tumors (colorectal, pancreatic, liver, lung, stomach, kidney cancers) at a significantly higher concentration than in healthy donors. Moreover, some studies suggested a potential association between hPG80 concentration changes and anti-cancer treatment efficacy in patients with gastro-intestinal and hepatocellular carcinomas. Finally, hPG80 might be a prognostic factor for overall survival in metastatic renal cell carcinoma cancer (mRCC) and in hepatocellular carcinoma (HCC). If these hypotheses were validated, hPG80 might help better stratify patients according to their prognosis, and also become a tool to monitor relapse and predict treatment response. Prospective validation studies are on-going. |
| Publication | Bulletin Du Cancer |
| Volume | 109 |
| Issue | 6 |
| Pages | 707-713 |
| Date | 2022-06 |
| Journal Abbr | Bull Cancer |
| Language | fre |
| DOI | 10.1016/j.bulcan.2022.03.009 |
| ISSN | 1769-6917 |
| Short Title | [hPG80 and cancer |
| Library Catalog | PubMed |
| Extra | PMID: 35597620 |
| Tags | Biomarkers, Biomarkers, Tumor, Biomarqueur sanguin, Blood biomarker, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinome hépatocellulaire (CHC), Circulating progastrin, ELISA assay, HPG(80), Humans, Kidney Neoplasms, Liver Neoplasms, Monitoring, Physiologic, Multi-cancer, Multicancer, Neoplasm Recurrence, Local, Progastrine circulante, Prognosis, Test Elisa |
| Date Added | 2022/08/30 - 15:59:41 |
| Date Modified | 2024/10/10 - 16:31:32 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
